NHNatalia Honcharuk

Natalia Honcharuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalia Honcharuk has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Impact of Clinical Trials on Ukraine’s Healthcare System During the War: Regulatory Changes, Organizational Innovations

    by Vasyl Mykhalchuk, Natalia Honcharuk

    The relevance of clinical trials (CTs) is determined by their key role in the development of modern medicine and healthcare. The objective: to summarize the impact of CTs on the Ukrainian healthcare system in the context of a full-scale war, to outline regulatory transformations, organizational models for the continuation of CTs, ethical and security challenges, as well as the consequences for patient access to innovative therapies and system sustainability. Materials and methods. The work used methods of analytical review of scientific publications, international recommendations, regulatory and legal acts of the Ministry of Health (MOH) of Ukraine, as well as reports of the State Expert Center (SEC) of the MOH. Sources were selected according to the criteria of relevance (2020–2025), availability of data on the impact of crisis conditions on CTs and their areas of application. A narrative review of regulatory legal acts, analytical reports of the SEC of the Ministry of Health of Ukraine, documents of the EMA (European Medicines Agency), the EC (European Commission / Ethics Committee), as well as the CTCG (Clinical Trial Coordination Group). A review of publications in peer-reviewed journals (The Lancet, JCO Global Oncology, Human Reproduction Update, Fertility and Sterility) and professional reports of ECO (European Cancer Organisation), American Society of Clinical Oncology (ASCO), IFFS (International Federation of Fertility Societies), UNFPA (United Nations Population Fund). Results. Despite a significant reduction in the number of active CTs in 2022–2023, the sector has taken some steps to adapt through accelerated examinations, harmonization of the CT Procedure with European requirements, the introduction of risk-based and decentralized management, participant transfer, and flexible monitoring. Conclusions. It has been established that CTs during wartime perform a dual role: 1) ensure patient access to potentially life-saving interventions; 2) serve as a driver of regulatory convergence and increase the resilience of the healthcare system. The review suggests that further steps are needed, including institutionalization of crisis protocols, digitalization of procedures, development of a national infrastructure of decentralized CTs, and international data coordination.

  • Open Access

    Successful pregnancy: simply about the complicated

    by T.F. Tatarchuk, V.I. Pyrogova, N.P. Goncharuk, N.Y. Pedachenko, D.G. Konkov

    Progesterone is a key hormone essential for maintaining pregnancy. Its deficiency can lead to the risk of miscarriage, recurrent pregnancy loss, and unsuccessful attempts at in vitro fertilization. In clinical practice, progestogens are used for luteal phase support, particularly in women with corpus luteum insufficiency or in assisted reproductive technologies cycles.After the synthetic progestogen 17-hydroxyprogesterone caproate was withdrawn from the pharmaceutical market due to low efficacy and multiple side effects, only two effective agents remain in obstetrics and reproductive medicine – progesterone and dydrogesterone.Dydrogesterone is a synthetic analog of natural progesterone with high oral bioavailability, making it a convenient alternative to other forms of progestogens. It selectively binds to progesterone receptors, ensuring stable endometrial support and promoting early pregnancy maintenance. Unlike some other progestogens, dydrogesterone has no androgenic, estrogenic, or glucocorticoid effects, which contributes to its better tolerability.The evidence base supporting dydrogesterone’s efficacy includes numerous randomized controlled trials, particularly LOTUS I and LOTUS II, which demonstrated that oral dydrogesterone is as effective as vaginal progesterone for luteal phase support at in vitro fertilization cycles. Additionally, multiple meta-analyses confirm that dydrogesterone use in the first trimester significantly reduces the risk of miscarriage, and over 70 studies have confirmed the high efficacy and safety of its molecule for both women and fetuses.The safety of dydrogesterone is particularly important. The international expert group on the safety of progestogens in early pregnancy REASSURE concluded that there is currently no basis for making statements about a causal relationship between the use of dydrogesterone in the first trimester and the risk of congenital malformations.Thus, due to its proven efficacy and excellent safety profile, supported by over 60 years of clinical use, dydrogesterone is the optimal choice for luteal phase support in both natural cycles and assisted reproductive technologies.

  • Open Access

    Resolution of the I Ukrainian forum on miscarriages

    by T.F. Tatarchuk, N.P. Honcharuk, N.Y. Pedachenko, D.H. Konkov, A.M. Kalinchuk, E.H. Manzhalii, T.K. Znamenska, T.M. Tutchenko, M.V. Haytovych

    Today, there is an urgent need to develop and implement a regulatory document on abortion. This is due to the catastrophic state of reproduction of the Ukrainian population – the annual decrease in the number of labor, birth rates and the demographic crisis in Ukraine in general. Pregnancy loss not only causes obstetric complications, but also causes significant damage of the mental health of the woman and her partner, including depression and post-traumatic stress disorder.This resolution is a joint position of the leading specialists of Ukraine on the issue of miscarriages based on domestic experience, results of randomized controlled trials and meta-analyses, as well as clinical recommendations of scientific societies of the world. The presented information is designed to help improve clinical approaches to the management of miscarriage in today’s conditions, in order to save every pregnancy and to not lose a baby.During the Forum, the practical issues of diagnosis and treatment of miscarriage, modern management of threatened and habitual miscarriage, hormonal support of pregnant women and the use of progestogens, the influence of the first half of pregnancy on the birth of a healthy child, the impact of liver diseases on the choice of therapy in a pregnant woman, and others issues were considered.World clinical experience has convincingly proven the high effectiveness of progestogens in the therapy of threatened and repeated miscarriages. However, not all progestogens are equally effective in reducing the risk of miscarriage and live birth in case of threatened miscarriage. Micronized progesterone and dydrogesterone are the most effective. Dydrogesterone differs from progesterone in its mechanism of action and affinity for progesterone receptors. A strong evidence base has been accumulated about a high profile of effectiveness and a low frequency of maternal and fetal complications for dydrogesterone, the use of which is approved by leading foreign associations.Drug interactions and their effects on the liver should also be taken into account. Drugs that are indicated for pregnant women should be prescribed in the smallest therapeutic dose, which should be effective.

  • Open Access

    Progestagens in high-risk pregnancy. What we know today

    by N.Y. Pedachenko, N.P. Goncharuk, E.F. Chaikivska, T.F. Tatarchuk, T.M. Tutchenko

    Miscarriage remains an important global problem: 23 million miscarriages are registered annually in the world, i.e. 44 pregnancy losses every minute, and the total risk of miscarriage is 15.3% of all pregnancies. Effective methods of pregnancy preservation (in case of idiopathic miscarriage and threatened miscarriage) include lifestyle modification and progestagen therapy. Progesterone is the main hormone necessary to maintain pregnancy. The effectiveness of progestogens among medical methods that increase the chances of pregnancy preservation has been proven by numerous studies. Effectiveness and safety of various types of progestogens during pregnancy have been studied. As a result, progesterone and dydrogesterone became the only progestogens approved for use in obstetrics – micronized progesterone and dydrogesterone reduce the frequency of miscarriage in women with clinical diagnoses of threatened miscarriage and idiopathic recurrent miscarriage. In addition, the progestogens safety has been carefully studied in modern randomized studies, prospective trials and meta-analyses and the same safety profile of dydrogesterone and micronized progesterone for pregnant women and the fetus has been proven. Studies have shown that oral dydrogesterone has relatively low antagonistic activity at glucocorticoid and mineralocorticoid receptors compared to progesterone and therefore well tolerated. Oral dydrogesterone due to the peculiarities of structure has improved bioavailability compared to progesterone, which allows a woman to avoid the inconvenience and discomfort associated with the intravaginal or intramuscular use of progesterone. In addition, dydrogesterone has a 1.5 times higher affinity for progesterone receptors compared to micronized progesterone and a pronounced anti-inflammatory and immunomodulation effect, which provides certain clinical advantages for patients after recurrent pregnancy losses. Thus, progestogens are indicated for all patients with recurrent pregnancy losses from the moment of receiving a positive pregnancy test, as they reduce the risk of miscarriage. It is important that the use of progestagen drugs during the first and second trimester of pregnancy is not associated with side effects


  • Open Access

    Clinical case of expectant tactics of scar pregnancy and childbirth in the III trimester

    by O.D. Shchurevska, N.P. Honcharuk

    One of the rare complications of a previous cesarean section is pregnancy with implantation in the area of the postoperative scar. The literature describes isolated reports of this pathology, which relate to early pregnancy. The forecast and tactics of their management are debatable issues.This article presents a case of successful monitoring of pregnancy and childbirth of a patient with a combined pathology: the placenta in the area of the cesarean scar with its diastase and central placenta previa with the germination of the uterine wall.The 34-year-old pregnant woman (III pregnancy and II expected childbirth) during ultrasound examination central a placenta previa was diagnosed. It had ingrowth into the uterine wall creating defect of the cesarean scar. Informed about the possible risks, patient strongly insisted on prolonging the pregnancy. Since 23 weeks she was in an obstetric hospital for the possibility of urgent surgery. Within 37 weeks, a planned caesarean section was performed by bottom access with subsequent extirpation of the uterus. Literary data from different countries almost all describe the completion of cesarean scar pregnancy in the first and second trimesters. Due to the rarity, heterogeneity of groups and the lack of a single protocol for the management of this pathology, combined or modified approaches to treatment are more often used. Primary prevention should begin at the stage of preventing a high frequency of cesarean section, reviewing the indications for it and conducting a truly justified surgery. Preconceprion care should be mandatory when planning the next pregnancy. Great attention should be paid to the localization of the chorion in the protocol of the screening ultrasound examination of the first trimester if there is uterine scar. In the case of a cesarean scar pregnancy, we cannot recommend an expectant tactics at this stage. Any method that eliminates cesarean scar pregnancy, especially in the early term, will saving the body and future fertility, as well as reduces morbidity and mortality.